AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

13,304.00p
   
  • Change Today:
    -342.00p
  • 52 Week High: 15,316.00
  • 52 Week Low: 11,460.00
  • Currency: UK Pounds
  • Shares Issued: 1,551.07m
  • Volume: 2,039,675
  • Market Cap: £206,354m
  • RiskGrade: 123
  • Beta: 0.00

Latest ShareCast News

Astrazeneca secures EU and US approvals for Klygefa in rare muscle disorder

By Iain Gilbert

Date: Monday 16 Nov 2026

(Sharecast News) - Drugmaker Astrazeneca said on Monday that its rare disease division Alexion had secured regulatory approvals for Klygefa (gefurulimab) in both the European Union and the United States for the treatment of adults with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody positive.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 13,304.00p
Change Today -342.00p
% Change -2.51 %
52 Week High 15,316.00
52 Week Low 11,460.00
Volume 2,039,675
Shares Issued 1,551.07m
Market Cap £206,354m
Beta 0.00
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
93.69% below the market average93.69% below the market average93.69% below the market average93.69% below the market average93.69% below the market average
90.24% below the sector average90.24% below the sector average90.24% below the sector average90.24% below the sector average90.24% below the sector average
Price Trend
11.71% above the market average11.71% above the market average11.71% above the market average11.71% above the market average11.71% above the market average
48.84% above the sector average48.84% above the sector average48.84% above the sector average48.84% above the sector average48.84% above the sector average
Income
65.82% below the market average65.82% below the market average65.82% below the market average65.82% below the market average65.82% below the market average
33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average33.33% below the sector average
Growth
86.52% above the market average86.52% above the market average86.52% above the market average86.52% above the market average86.52% above the market average
64.29% above the sector average64.29% above the sector average64.29% above the sector average64.29% above the sector average64.29% above the sector average

What The Brokers Say

Strong Buy 10
Buy 8
Neutral 5
Sell 0
Strong Sell 0
Total 23
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  1st Interim 2nd Interim
Ex-Div 06-Aug-26 19-Feb-26
Paid 08-Sep-26 23-Mar-26
Amount 106.00¢ 217.00¢

Trades for 19-Nov-2026

Time Volume / Share Price
09:57 285,932 @ 13,672.00p
16:40 50,000 @ 13,308.60p
16:37 1,200 @ 13,304.00p
16:36 1,200 @ 13,304.00p
16:36 1,200 @ 13,304.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page